Articles

  • 1 week ago | managedhealthcareexecutive.com | Patricia Weiser

    Patients with early-stage lung cancer were more likely to receive timely surgery and be treated at high-volume hospitals if they lived in a state that expanded Medicaid under the Affordable Care Act, according to a new study conducted by researchers at MD Anderson Cancer Center in Houston. The research was published last week in The Annals of Thoracic Surgery.

  • 1 week ago | medicalnewstoday.com | Patricia Weiser

    Opdivo Qvantig is a brand-name injection prescribed for certain types of cancer. It contains the active ingredients nivolumab and hyaluronidase-nvhy and belongs to the immunotherapy drug class. The Food and Drug Administration (FDA) has approved Opdivo Qvantig to treat several types of cancer. Examples include cancers of the kidneys, skin, lungs, head or neck, bladder, liver, and digestive tract.

  • 2 weeks ago | medicalnewstoday.com | Patricia Weiser

    It’s not known whether Rystiggo (rozanolixizumab) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may determine whether you should receive the drug during this time. It isn’t known whether it’s safe to receive Rystiggo during pregnancy. Based on animal studies, Rystiggo may cause fetal harm. However, animal studies don’t always predict the drug’s effects in humans.

  • 3 weeks ago | verywellhealth.com | Patricia Weiser

    Acid reflux occurs when stomach acid flows back into the esophagus, causing discomfort and symptoms like heartburn, a sour taste, and throat irritation. While occasional reflux is normal and usually goes away on its own or can be treated by an over-the-counter (OTC) antacid, ongoing symptoms may lead you to look for other remedies. Besides prescription and OTC medications, some people find relief from dietary supplements to ease symptoms.

  • 3 weeks ago | managedhealthcareexecutive.com | Patricia Weiser

    New research, published in the New England Journal of Medicine in February 2025, adds support for the safety and efficacy of Bizengri (zenocutuzumab), a bispecific antibody drug, in patients with advanced NRG1 fusion–positive cancers.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →